NanoViricides Inc. (NNVC)

[loanranger]

[e-mail]
3:07 PM (1 hour ago)

No one seems to get this relationship right although it’s rather simple

There are two elements to this

#1) The R&D element where TheraCour's employees do the drug development and we reimburse TheraCour on a cost + 30% basis. In a prior company, when I used outside people, I paid the contractor who supplied them at cost +30%

#2) Royalties on sales. TheraCour receives 15% of any revenue dollar that NNVC receives from the licensing and sales of our drugs to a pharma partner. Thus, for every dollar we receive, 15¢ goes to TheraCour and 85¢ stays with us.

Think of NNVC as the “big pharma” who is paying TheraCour, (the biotech company), its development costs plus a 30% override. Then when there are sales, the “biotech” gets a royalty stream (15% of every dollar we receive)

That’s all there is to it!

Eugene Seymour MD MPH
Chief Executive Officer